MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

BioCryst Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

7.32 -1.35

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

7.15

Max

7.42

Galvenie mērījumi

By Trading Economics

Ienākumi

-13M

-27M

Pārdošana

14M

132M

EPS

-0.13

Peļņas marža

-20.371

Darbinieki

580

EBITDA

-13M

-1.2M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+98.25% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 5. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-86M

1.6B

Iepriekšējā atvēršanas cena

8.67

Iepriekšējā slēgšanas cena

7.32

BioCryst Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 3. apr. 23:04 UTC

Top Ziņas

JPMorgan Raises Risk of U.S., Global Recession to 60%

2025. g. 3. apr. 22:40 UTC

Galvenie tirgus virzītāji

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

2025. g. 3. apr. 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

2025. g. 3. apr. 18:51 UTC

Iegādes, apvienošanās, pārņemšana

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

2025. g. 3. apr. 23:43 UTC

Tirgus saruna

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

2025. g. 3. apr. 23:41 UTC

Tirgus saruna

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

2025. g. 3. apr. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

2025. g. 3. apr. 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

2025. g. 3. apr. 21:43 UTC

Top Ziņas
Peļņas

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

2025. g. 3. apr. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 3. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 3. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 3. apr. 20:43 UTC

Tirgus saruna

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

2025. g. 3. apr. 20:34 UTC

Top Ziņas

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

2025. g. 3. apr. 20:23 UTC

Top Ziņas

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

2025. g. 3. apr. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

2025. g. 3. apr. 19:55 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 3. apr. 19:55 UTC

Tirgus saruna

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

2025. g. 3. apr. 19:21 UTC

Tirgus saruna

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

2025. g. 3. apr. 19:15 UTC

Tirgus saruna

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

2025. g. 3. apr. 18:45 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 3. apr. 18:45 UTC

Tirgus saruna

Gold Drops In Tariff Fallout -- Market Talk

2025. g. 3. apr. 18:39 UTC

Tirgus saruna

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

2025. g. 3. apr. 18:38 UTC

Top Ziņas

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

2025. g. 3. apr. 18:30 UTC

Top Ziņas

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

2025. g. 3. apr. 18:20 UTC

Tirgus saruna

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

2025. g. 3. apr. 18:18 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 3. apr. 18:17 UTC

Tirgus saruna

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

2025. g. 3. apr. 18:04 UTC

Tirgus saruna

US Sees More Job Openings in Construction, Transportation -- Market Talk

2025. g. 3. apr. 17:55 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

BioCryst Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

98.25% augšup

Prognoze 12 mēnešiem

Vidējais 14.73 USD  98.25%

Augstākais 30 USD

Zemākais 8 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi BioCryst Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

11 ratings

10

Pirkt

1

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.